Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $6.75 Consensus Price Target from Brokerages

Esperion Therapeutics, Inc. (NASDAQ:ESPR) has received an average recommendation of “Moderate Buy” from the six analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $6.75.

Several research analysts have recently issued reports on ESPR shares. JMP Securities reaffirmed a “market outperform” rating and issued a $4.00 target price (down previously from $7.00) on shares of Esperion Therapeutics in a research note on Tuesday, February 11th. Cantor Fitzgerald assumed coverage on shares of Esperion Therapeutics in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $8.00 price objective on the stock. The Goldman Sachs Group began coverage on shares of Esperion Therapeutics in a research report on Wednesday, December 18th. They set a “neutral” rating and a $4.00 target price for the company. Needham & Company LLC restated a “buy” rating and issued a $6.00 price target on shares of Esperion Therapeutics in a research report on Friday, December 13th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $16.00 price objective on shares of Esperion Therapeutics in a research note on Thursday, March 20th.

Hedge Funds Weigh In On Esperion Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Mackenzie Financial Corp raised its stake in Esperion Therapeutics by 116.1% during the 4th quarter. Mackenzie Financial Corp now owns 143,252 shares of the biopharmaceutical company’s stock worth $315,000 after buying an additional 76,965 shares during the period. Two Sigma Advisers LP raised its position in shares of Esperion Therapeutics by 0.4% during the fourth quarter. Two Sigma Advisers LP now owns 3,616,200 shares of the biopharmaceutical company’s stock worth $7,956,000 after purchasing an additional 16,100 shares during the period. Rafferty Asset Management LLC acquired a new stake in shares of Esperion Therapeutics during the fourth quarter worth about $82,000. ProShare Advisors LLC lifted its holdings in shares of Esperion Therapeutics by 75.2% during the 4th quarter. ProShare Advisors LLC now owns 62,549 shares of the biopharmaceutical company’s stock valued at $138,000 after purchasing an additional 26,843 shares in the last quarter. Finally, Nuveen Asset Management LLC grew its position in shares of Esperion Therapeutics by 48.6% in the 4th quarter. Nuveen Asset Management LLC now owns 3,119,253 shares of the biopharmaceutical company’s stock valued at $6,862,000 after purchasing an additional 1,020,243 shares during the period. 47.39% of the stock is owned by institutional investors.

Esperion Therapeutics Stock Down 6.8 %

Esperion Therapeutics stock opened at $1.50 on Friday. The business’s 50-day simple moving average is $1.78 and its 200 day simple moving average is $2.07. The stock has a market cap of $296.77 million, a price-to-earnings ratio of -2.34 and a beta of 1.04. Esperion Therapeutics has a 12-month low of $1.47 and a 12-month high of $3.94.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.